Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results

European Neuropsychopharmacology

Volumn 17, Issue 4, 2007, Pages 235-244

  Haro, Josep Maria ^a   Suarez, David ^a   Novick, Diego ^b   Brown, Jacqueline ^b   Usall, Judith ^a   Naber, Dieter ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotics; ; Clinical outcome; ; Effectiveness; ; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; AMENORRHEA; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EUROPE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HOSTILITY; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; SUBSTANCE ABUSE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 33846558834     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.09.005     Document Type: Article

References (30)

1. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., and Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J. Clin. Psychiatry 67 (2006) 453-460
2. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., and Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6 (2006) 8
3. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 158 (2001) 765-774
4. Cooper D., Moisan J., Gaudet M., Abdous B., and Gregoire J.P. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can. J. Psychiatry 50 (2005) 901-908
5. Covell N.H., Jackson C.T., Evans A.C., and Essock S.M. Antipsychotic prescribing practices in Connecticut's Public Mental Health System: rates of changing medications and prescribing styles. Schizophr. Bull. 28 (2002) 17-29
6. Curran M.P., and Perry C.M. Spotlight on amisulpride in schizophrenia. CNS Drugs 16 3 (2002) 207-211
7. Cutler A.J., Goldstein J.M., and Tumas J.A. Dosing and switching strategies for quetiapine fumarate. Clin. Ther. 24 (2002) 209-222
8. Guy G. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology. Revised (1976), National Institute of Mental Health, Rockville, Maryland
9. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., et al. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr. Scand. 107 (2003) 222-232
10. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 107 suppl 416 (2003) 16-23
11. Haro J.M., Edgell E., Novick D., Alonso J., Kennedy L., Jones P., et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111 (2005) 220-231
12. Haro J.M., Novick D., Belger M., Jones P.B., and the SOHO advisory board. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur. Psychiatr. 21 (2006) 41-47
13. Haro J.M., Kontodimas S., Negrin M.A., Ratcliffe M., Suarez D., and Windmeijer F. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl. Health Econ. Health Policy 5 1 (2006) 11-25
14. Janssen B., Gaebel W., Haerter M., Komaharadi F., Lindel B., and Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology 187 (2006) 229-236
15. Lambert M., Haro J.M., Novick D., Edgell E.T., Kennedy L., Ratcliffe M., et al. Olanzapine versus other antipsychotics in actual outpatient settings: 6-month safety results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111 (2005) 232-243
16. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 (1999) 51-68
17. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
18. McGorry P.D., Killackey E., Lambert M., Elkins K., and Lambert T. Summary Australian and New Zealand Clinical Practice Guidelines for the treatment of schizophrenia. Australas. Psychiatry 11 2 (2003) 1-13
19. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 (2003) 83-96
20. Peuskens J., Sienaert P., and De Hert M. Sexual dysfunction: the unspoken side-effect of antipsychotics. Eur. Psychiatr. 13 Suppl 1 (1998) 23-30
21. Sacket D.L., Haynes R.B., and Tugwell P. Clinical epidemiology. A Basic Science for Clinical Medicine (1985), Little, Brown and Company, Boston 159-169
22. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: schizophrenia trial design and protocol development. Schizophr. Bull. 29 (2003) 15-31
23. Swartz M.S., Perkins D.O., Stroup T.S., McEvoy J.P., Nieri J.M., and Haak D.C. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial. Schizophr. Bull. 29 (2003) 33-43
24. Tarsy D., Baldessarini R.J., and Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16 (2002) 23-45
25. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration study. Am. J. Psychiatry 154 (1997) 457-465
26. Valenstein M., Blow F.C., Copeland L.A., McCarthy J.F., Zeber J.E., Gillon L., Bigham C.R., and Stavanger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 30 (2004) 255-264
27. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 155 (2001) 230-233
28. Weiss K.A., Smith T.E., Hull J.W., Piper A.C., and Huppert J.D. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr. Bull. 28 (2002) 341-349
29. Whitworth A.B., and Fleischhacker W. Adverse effects of antipsychotic drugs. Int. Clin. Psychopharmacol. 9 Suppl 5 (1995) 21-27
30. Williams C.L., Johnstone B.M., Kesterson J.G., Javor K.A., and Schmetzer A.D. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med. Care 37 (1999) AS81-AS86